At $300,000 a year, Sarepta’s new drug is considered a steal
September 20, 2016 at 11:50 AM EDT
Eteplirsen could have been more than twice the price, an analyst said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.